HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 10/10/2012 -- Otelco, Inc. (NGM:OTT) is +0.431 - +18.75% from the previous close of $2.299. It traded between $2.30 - 2.84 with total traded volume of 1324812 shares. At Current Market Price, OTTis in distance of +47.18% from its 50-day Moving Average price of $1.8549 and -54.81% from its 200-day Moving Average price of $6.0411.Otelco Inc. (NAS: OTT) (TSX: OTT.un), a wireline telecommunication services provider in Alabama, Maine, Massachusetts, Missouri, New Hampshire, Vermont and West Virginia, today announced that it will release its 2012 third quarter financial and operational results after the close of trading on Tuesday, November 6, 2012. The Company will hold a conference call to discuss third quarter results on Wednesday
Can OTT Starts Rally From Here : CHECK HERE
E2open, Inc. (NGM:EOPN) is +2.07 - +15.75% from the previous close of $13.14. It traded between $13.23 - 15.25 with total traded volume of 478235 shares. At Current Market Price, EOPN is in distance of +10.40% from its 50-day Moving Average price of $13.7769 and +13.92% from its 200-day Moving Average price of $13.3519. E2open, Inc. (EOPN) posted second-quarter net income of $4.6 million or $0.19 per share, compared to a net loss of $2.4 million or $0.38 per share in the prior year period. Non-GAAP net income for the quarter was $0.5 million or $0.02 per share, compared to non-GAAP net loss of $1.9 million or $0.08 per share in the comparable quarter last year. On average, five analysts polled by Thomson Reuters expected the company to report a loss of $0.05 per share. Analysts' estimates typically exclude special items. Total revenue for the quarter rose to $22.89 million from $15.47 million in the year-ago quarter, while five analysts had a consensus revenue estimate of $17.39 million for the quarter.
Can EOPN Extends Rally? FIND OUT HERE
ORBCOMM Inc. (NGM:ORBC) is -0.29 - -7.57% from the previous close of $3.83. It traded between $3.34 - 3.81 with total traded volume of 215883 shares. At Current Market Price, ORBC is in distance of -3.35% from its 50-day Moving Average price of $3.6629 and +3.51% from its 200-day Moving Average price of $3.4199. ORBCOMM Inc. (NAS: ORBC) , a global satellite data communications company focused on two-way Machine-to-Machine (M2M) communications, today announced that the first prototype of its second generation of satellites (OG2) was launched on the Cargo Re-Supply Services (CRS-1) mission aboard the SpaceX Falcon 9 launch vehicle from Cape Canaveral, FL, on October 7, 2012 at 8:35 pm EST. The OG2 prototype satellite, flying as a secondary payload on this mission, was separated from the Falcon 9 launch vehicle at approximately 9:00 pm EST. However, due to an anomaly on one of the Falcon 9's first stage engines, the rocket did not comply with a pre-planned International Space Station (ISS) safety gate to allow it to execute the second burn.
How Should Investors React To ORBC Now? FIND OUT HERE
Neuralstem, Inc. (AMEX:CUR) is -0.09 - -7.03% from the previous close of $1.28. It traded between $1.16 - 1.31 with total traded volume of 1923981 shares. At Current Market Price, CUR is in distance of +22.97% from its 50-day Moving Average price of $0.9677 and +26.17% from its 200-day Moving Average price of $0.9432. Neuralstem, Inc. (NYSE Amex: CUR) announced that Eva Feldman, MD, PhD, principal investigator of the Phase I trial to test Neuralstem's NSI-566 spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), updated data on the trial at the American Neurological Association annual meeting in Boston, MA, yesterday. (http://www.aneuroa.org/i4a/pages/index.cfm?pageid=3311). Dr. Feldman, who is President of the American Neurological Association, presented interim results on all 18 procedures in 15 patients, including the last three patients from earlier cohorts who received second procedures. The trial will conclude six months after the last patient was treated, which was in August.
Should Investors Buy or Sell CUR Now? FIND HERE
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)